Proposed academic endorsement of postgraduate fellowship and physician certification programs would mark a major milestone in ISSCA’s international education platform.

MIAMI, FL — [RELEASE DATE] — Regenerative Medical Technology Group, Inc. (OTC: RMTG) (“RMTG” or the “Company”) announced a collaboration between its physician education division, the International Society for Stem Cell Application (ISSCA), and the University of Buenos Aires (UBA), one of Latin America’s most established academic institutions.

Under the collaboration as described by management, ISSCA’s postgraduate Fellowship in Cell Therapy and Tissue Engineering, together with designated physician certification and training programs, are intended to receive academic endorsement from UBA, subject to the scope and terms of the institutions’ agreement.

Founded in 2009, ISSCA has developed an international platform for physician education in regenerative medicine, cellular therapies and tissue engineering, training thousands of medical professionals in more than 40 countries.

“This collaboration represents one of the most meaningful academic milestones in ISSCA’s history,” said Emiliano Herrera, Director of ISSCA. “For more than 17 years, our organization has focused on advancing physician education in regenerative medicine. Recognition by an institution with the academic tradition of the University of Buenos Aires is a powerful acknowledgment of that work.”

The initiative is intended to strengthen the academic profile of ISSCA’s postgraduate and continuing education offerings, enhance value for participating physicians and support expansion of its international education programs.

“For our physicians, this adds another dimension of academic recognition to the programs we have built over nearly two decades,” Herrera added. “We believe it can open an important new chapter in ISSCA’s global development.”

Any university endorsement will apply only to programs expressly identified in the finalized agreement and does not itself confer a UBA degree, professional license or regulatory authorization.

About the Operating Division

The International Society for Stem Cell Application (ISSCA) is the physician education division of Global Stem Cells Group, providing postgraduate training, certifications, conferences and practical programs in regenerative medicine. www.issca.com

About RMTG

Regenerative Medical Technology Group, Inc. (OTC: RMTG) operates an integrated regenerative medicine platform through Global Stem Cells Group and its specialized businesses. www.rmtg.com

Forward-Looking Statements

This press release contains forward-looking statements under applicable securities laws, including statements regarding anticipated growth, revenues, product adoption, academic collaboration, product introductions and geographic expansion. Actual results may differ materially due to regulatory developments, operational execution, market acceptance, competition and other risks. These statements are not guarantees of future performance. The Company undertakes no duty to update them except as required by law.

Investor Relations

Regenerative Medical Technology Group, Inc. | OTC: RMTG | www.rmtg.com |

International training programs bring advanced regenerative medicine education directly to physicians across Latin America and the Middle East.

MIAMI, FL — November 6, 2026 — Regenerative Medical Technology Group, Inc. (OTC: RMTG) (“RMTG” or the “Company”) announced that Cellgenic, its advanced biologics and regenerative therapeutics division operating through Global Stem Cells Group, is accelerating its international expansion through a series of physician-focused workshops across key markets.

The initiative combines biologics commercialization with direct physician education, practical training and ongoing professional support. Workshops are underway or scheduled across Cancun, Peru, Paraguay, Colombia, Brazil and Argentina, with Dubai and additional markets planned.

Designed for groups of approximately 50 physicians, the workshops generally run one to two days. Expert-led sessions address peptides, cellular therapies, exosomes, clinical considerations, dosing principles, combination strategies, protocol development and appropriate use under applicable regulatory requirements.

“Cellgenic is entering a very exciting phase of international expansion,” said Sarah Barroso, CEO of Cellgenic. “Physicians need more than access to advanced biologics. They need knowledge, confidence and ongoing technical guidance. By bringing that expertise directly into their markets, we believe we can strengthen customer loyalty, accelerate product adoption and support sustained commercial growth.”

Management expects the initiative to improve physician onboarding, deepen existing customer relationships and create opportunities for repeat purchasing and expanded sales of Cellgenic products. These outcomes remain subject to execution, physician demand and market conditions.

“We are building a worldwide community of physicians who understand our technologies and see Cellgenic as a long-term partner,” Barroso added. “We expect that community to create additional opportunities as we continue expanding our workshop calendar.”

The Company expects to add further physician education programs and international markets during 2027.

About the Operating Division

Cellgenic is the advanced biologics and regenerative medicine commercialization division of Global Stem Cells Group, focused on cellular technologies, regenerative products and physician engagement. www.cellgenic.com

About RMTG

Regenerative Medical Technology Group, Inc. (OTC: RMTG) operates an integrated regenerative medicine platform through Global Stem Cells Group and its specialized businesses. www.rmtg.com

Forward-Looking Statements

This press release contains forward-looking statements under applicable securities laws, including statements regarding anticipated growth, revenues, product adoption, academic collaboration, product introductions and geographic expansion. Actual results may differ materially due to regulatory developments, operational execution, market acceptance, competition and other risks. These statements are not guarantees of future performance. The Company undertakes no duty to update them except as required by law.

Investor Relations

Regenerative Medical Technology Group, Inc. | OTC: RMTG | www.rmtg.com |

A December 12 physician event in Buenos Aires will introduce a new aesthetic cellular technology initiative within Cellgenic’s expanding regenerative medicine portfolio.

MIAMI, FL — November 6, 2026 — Regenerative Medical Technology Group, Inc. (OTC: RMTG) (“RMTG” or the “Company”) announced that its advanced biologics division, Cellgenic, is preparing to introduce an autologous fibroblast product developed through its laboratory operations in Buenos Aires, Argentina.

The initiative expands Cellgenic’s work in cellular technologies for aesthetic medicine and complements its existing portfolio spanning regenerative biologics, stem cell technologies, exosomes and peptides.

Autologous fibroblast technology involves cells derived from an individual’s own tissue and is an area of research and development for potential aesthetic and tissue applications. Any clinical commercialization or use will depend on the applicable regulatory authorizations, medical requirements and product-specific evidence.

Cellgenic plans to formally present the technology at a physician networking and product introduction event in Buenos Aires on December 12, 2026, bringing together medical professionals, industry leaders and commercial partners.

“Argentina is becoming one of the most important markets in our international expansion strategy,” said Dave Christensen, CEO and President of Regenerative Medical Technology Group. “With Cellgenic’s expanding laboratory and commercial presence, we are building a platform that extends beyond traditional biologics distribution. Autologous fibroblast technology is an exciting addition to our aesthetic medicine pipeline, and our ambition is to establish Cellgenic as a leading force in the Argentine regenerative medicine market.”

The Company intends to support physician education, scientific collaboration and further product development in Argentina while continuing to expand its commercial infrastructure.

“Our strategy combines laboratory capabilities, a strong commercial organization and continuous physician education,” Christensen added. “As we introduce additional technologies, we expect Argentina to become an increasingly important contributor to Cellgenic’s international growth.”

About the Operating Division

Cellgenic is the advanced biologics and regenerative medicine commercialization division of Global Stem Cells Group, focused on cellular technologies, regenerative products and physician engagement. www.cellgenic.com

About RMTG

Regenerative Medical Technology Group, Inc. (OTC: RMTG) operates an integrated regenerative medicine platform through Global Stem Cells Group and its specialized businesses. www.rmtg.com

Forward-Looking Statements

This press release contains forward-looking statements under applicable securities laws, including statements regarding anticipated growth, revenues, product adoption, academic collaboration, product introductions and geographic expansion. Actual results may differ materially due to regulatory developments, operational execution, market acceptance, competition and other risks. These statements are not guarantees of future performance. The Company undertakes no duty to update them except as required by law.

Investor Relations

Regenerative Medical Technology Group, Inc. | OTC: RMTG | www.rmtg.com |